Avacopan
FDA-approved product (capsule, oral), marketed as Tavneos.
- Registered studies
- 26
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Anti-neutrophil antibody associated vasculitis
- Anti-neutrophil cytoplasmic antibody-associated vasculitis
- Granulomatosis with Polyangiitis
- Microscopic polyangiitis
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Complement inhibitors
- FDA pharmacologic class
- Complement 5a Receptor Antagonist FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA59.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli43.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae34.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis71.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
26registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Avacopan with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- AfamelanotideExisting use: Erythropoietic protoporphyria65.1% AI-predicted activityagainst MRSA23 registered studies
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives64.9% AI-predicted activityagainst MRSALab records exist50+ registered studies
- Imatinib MesylateExisting use: Acute lymphoblastic leukemia, B-cell acute lymphoblastic leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and 7 more64.9% AI-predicted activityagainst MRSA50+ registered studies
- Naldemedine TosylateExisting use: Constipation, Constipation disorder64.8% AI-predicted activityagainst MRSA1 registered study
- Vorapaxar SulfateExisting use: Myocardial infarction, Peripheral arterial disease, Recurrent thrombophlebitis and 1 more64.8% AI-predicted activityagainst MRSA15 registered studies
- Rimegepant SulfateExisting use: Migraine disorder64.7% AI-predicted activityagainst MRSA50+ registered studies
- Terlipressin AcetateExisting use: Hepatorenal syndrome, Kidney failure, Renal insufficiency64.6% AI-predicted activityagainst MRSA7 registered studies
- Bremelanotide AcetateExisting use: Mental or behavioural disorder, Physiological sexual disorder, Sexual dysfunction64.5% AI-predicted activityagainst MRSA1 registered study
- Tazemetostat HydrobromideExisting use: Follicular lymphoma, Neoplasm, Sarcoma64.4% AI-predicted activityagainst MRSA3 registered studies
- Isavuconazonium SulfateExisting use: Aspergillosis, Mucormycosis64.3% AI-predicted activityagainst MRSA50+ registered studies
- Nirogacestat HydrobromideExisting use: Gastrointestinal desmoid tumor64.2% AI-predicted activityagainst MRSA1 registered study
- Prasugrel HydrochlorideExisting use: Acute coronary syndrome, Hemorrhage, Intermediate coronary syndrome and 1 more64.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
A Study of CCX168 in Japanese and Caucasian Healthy Adult Males
NCT05988008 · start 2017-10-23
Registered record
- Registry ID
- NCT05988008
- Conditions
- Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
- Interventions
- CCX168; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2017-10-23
- Completion
- 2018-09-20
- Enrolment
- 80
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAnti-neutrophil Cytoplasmic Antibody-associated VasculitisInterventionCCX168; PlaceboPhasePhase 1Registry statusCompletedControlled Trial Evaluating Avacopan in C3 Glomerulopathy
NCT03301467 · start 2017-09-29
Registered record
- Registry ID
- NCT03301467
- Conditions
- C3 Glomerulopathy (C3G)
- Interventions
- Avacopan; Avacopan Matching Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2017-09-29
- Completion
- 2021-10-27
- Enrolment
- 57
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionC3 Glomerulopathy (C3G)InterventionAvacopan; Avacopan Matching PlaceboPhasePhase 2Registry statusCompletedA Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis
NCT02994927 · start 2017-03-15
Registered record
- Registry ID
- NCT02994927
- Conditions
- ANCA-Associated Vasculitis
- Interventions
- Avacopan; Prednisone; Cyclophosphamide; Rituximab; Azathioprine
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2017-03-15
- Completion
- 2019-11-01
- Enrolment
- 331
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionANCA-Associated VasculitisInterventionAvacopan; Prednisone; Cyclophosphamide; Rituximab +1 morePhasePhase 3Registry statusCompletedA Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications
NCT06004947 · start 2016-01-14
Registered record
- Registry ID
- NCT06004947
- Conditions
- Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
- Interventions
- CCX168; Midazolam; Celecoxib; Itraconazole; Rifampicin
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2016-01-14
- Completion
- 2016-06-10
- Enrolment
- 32
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAnti-neutrophil Cytoplasmic Antibody-associated VasculitisInterventionCCX168; Midazolam; Celecoxib; Itraconazole +1 morePhasePhase 1Registry statusCompletedA Study in Healthy Volunteers to Evaluate the Pharmacokinetic Food Effect and Cardiac Safety of CCX168
NCT05988021 · start 2015-12-03
Registered record
- Registry ID
- NCT05988021
- Conditions
- Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
- Interventions
- CCX168
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2015-12-03
- Completion
- 2016-05-25
- Enrolment
- 16
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAnti-neutrophil Cytoplasmic Antibody-associated VasculitisInterventionCCX168PhasePhase 1Registry statusCompletedComplement Inhibition in aHUS Dialysis Patients
NCT02464891 · start 2015-06-04
Registered record
- Registry ID
- NCT02464891
- Conditions
- Atypical Hemolytic Uremic Syndrome
- Interventions
- CCX168
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Terminated
- Start
- 2015-06-04
- Completion
- 2017-07-13
- Enrolment
- 6
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAtypical Hemolytic Uremic SyndromeInterventionCCX168PhasePhase 2Registry statusTerminatedOpen-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade
NCT02384317 · start 2015-03-27
Registered record
- Registry ID
- NCT02384317
- Conditions
- Immunoglobulin A Nephropathy
- Interventions
- CCX168
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2015-03-27
- Completion
- 2018-06-01
- Enrolment
- 7
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionImmunoglobulin A NephropathyInterventionCCX168PhasePhase 2Registry statusCompletedClinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis
NCT02222155 · start 2015-02-04
Registered record
- Registry ID
- NCT02222155
- Conditions
- ANCA-associated Vasculitis
- Interventions
- CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids; CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids; Placebo, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2015-02-04
- Completion
- 2016-07-19
- Enrolment
- 42
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionANCA-associated VasculitisInterventionCCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids; CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids; Placebo, twice daily, plus cyclophosphamide/rituximab plus glucocorticoidsPhasePhase 2Registry statusCompletedA Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy Participants
NCT06004960 · start 2014-10-20
Registered record
- Registry ID
- NCT06004960
- Conditions
- Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
- Interventions
- [14C]CCX168
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2014-10-20
- Completion
- 2014-12-05
- Enrolment
- 6
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAnti-neutrophil Cytoplasmic Antibody-associated VasculitisIntervention[14C]CCX168PhasePhase 1Registry statusCompletedA Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis
NCT01363388 · start 2011-09
Registered record
- Registry ID
- NCT01363388
- Conditions
- Vasculitis
- Interventions
- Placebo; CCX168
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2011-09
- Completion
- 2016-01
- Enrolment
- 67
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionVasculitisInterventionPlacebo; CCX168PhasePhase 2Registry statusCompletedA Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CCX168 in Healthy Participants
NCT05984251 · start 2009-12-21
Registered record
- Registry ID
- NCT05984251
- Conditions
- Vasculitis; Systemic Lupus Erythematosus (SLE)
- Interventions
- CCX168; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2009-12-21
- Completion
- 2011-04-11
- Enrolment
- 48
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionVasculitis; Systemic Lupus Erythematosus (SLE)InterventionCCX168; PlaceboPhasePhase 1Registry statusCompleted